Clinical expansion Target growth through additional anatomical indications and joint approvals by leveraging HealthpointCapital partnership history and past regulatory expansion activity to drive new US and EU indications for the IlluminOss System.

Strategic partnerships Leverage existing investor and potential OEM/trauma device partnerships to accelerate market entry in mid to large hospital networks, focusing on expanding adoption with FDA-cleared fracture fixation system collaborators.

Minimally invasive edge Position the system’s percutaneous delivery and rapid stabilization as a productivity and patient throughput advantage for trauma and fracture clinics, highlighting reduced recovery times to attract adoption by high-volume orthopedic centers.

Key accounts Prioritize relationships with hospital systems and regional distributors that service high-incidence fracture locations (humerus, radius/ulna, clavicle, pelvis) and leverage existing sales channels to broaden footprint in the US and Europe.

Technology lead Emphasize the proprietary light-curable polymer and intramedullary balloon approach as a differentiator against traditional fixation, using case studies and surgeon testimonials to drive hospital procurement conversations and expand procedural volumes.